CINXE.COM

<!DOCTYPE html> <html lang="en" dir="ltr"> <head>  <script async src="https://www.googletagmanager.com/gtag/js?id=G-P63WKM1TM1"></script> <script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-P63WKM1TM1'); </script>  <script type="text/javascript" > (function(m,e,t,r,i,k,a){m[i]=m[i]||function(){(m[i].a=m[i].a||[]).push(arguments)}; m[i].l=1*new Date(); for (var j = 0; j < document.scripts.length; j++) {if (document.scripts[j].src === r) { return; }} k=e.createElement(t),a=e.getElementsByTagName(t)[0],k.async=1,k.src=r,a.parentNode.insertBefore(k,a)}) (window, document, "script", "https://mc.yandex.ru/metrika/tag.js", "ym"); ym(55165297, "init", { clickmap:false, trackLinks:true, accurateTrackBounce:true, webvisor:false }); </script> <noscript><div><img src="https://mc.yandex.ru/watch/55165297" style="position:absolute; left:-9999px;" alt="" /></div></noscript>    <title>Search results for: invasive breast carcinoma (IBC)</title> <meta name="description" content="Search results for: invasive breast carcinoma (IBC)"> <meta name="keywords" content="invasive breast carcinoma (IBC)"> <meta name="viewport" content="width=device-width, initial-scale=1, minimum-scale=1, maximum-scale=1, user-scalable=no"> <meta charset="utf-8"> <link href="https://cdn.waset.org/favicon.ico" type="image/x-icon" rel="shortcut icon"> <link href="https://cdn.waset.org/static/plugins/bootstrap-4.2.1/css/bootstrap.min.css" rel="stylesheet"> <link href="https://cdn.waset.org/static/plugins/fontawesome/css/all.min.css" rel="stylesheet"> <link href="https://cdn.waset.org/static/css/site.css?v=150220211555" rel="stylesheet"> </head> <body> <header> <div class="container"> <nav class="navbar navbar-expand-lg navbar-light"> <a class="navbar-brand" href="https://waset.org"> <img src="https://cdn.waset.org/static/images/wasetc.png" alt="Open Science Research Excellence" title="Open Science Research Excellence" /> </a> <button class="d-block d-lg-none navbar-toggler ml-auto" type="button" data-toggle="collapse" data-target="#navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"> <span class="navbar-toggler-icon"></span> </button> <div class="w-100"> <div class="d-none d-lg-flex flex-row-reverse"> <form method="get" action="https://waset.org/search" class="form-inline my-2 my-lg-0"> <input class="form-control mr-sm-2" type="search" placeholder="Search Conferences" value="invasive breast carcinoma (IBC)" name="q" aria-label="Search"> <button class="btn btn-light my-2 my-sm-0" type="submit"><i class="fas fa-search"></i></button> </form> </div> <div class="collapse navbar-collapse mt-1" id="navbarMenu"> <ul class="navbar-nav ml-auto align-items-center" id="mainNavMenu"> <li class="nav-item"> <a class="nav-link" href="https://waset.org/conferences" title="Conferences in 2024/2025/2026">Conferences</a> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/disciplines" title="Disciplines">Disciplines</a> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/committees" rel="nofollow">Committees</a> </li> <li class="nav-item dropdown"> <a class="nav-link dropdown-toggle" href="#" id="navbarDropdownPublications" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false"> Publications </a> <div class="dropdown-menu" aria-labelledby="navbarDropdownPublications"> <a class="dropdown-item" href="https://publications.waset.org/abstracts">Abstracts</a> <a class="dropdown-item" href="https://publications.waset.org">Periodicals</a> <a class="dropdown-item" href="https://publications.waset.org/archive">Archive</a> </div> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/page/support" title="Support">Support</a> </li> </ul> </div> </div> </nav> </div> </header> <main> <div class="container mt-4"> <div class="row"> <div class="col-md-9 mx-auto"> <form method="get" action="https://publications.waset.org/abstracts/search"> <div id="custom-search-input"> <div class="input-group"> <i class="fas fa-search"></i> <input type="text" class="search-query" name="q" placeholder="Author, Title, Abstract, Keywords" value="invasive breast carcinoma (IBC)"> <input type="submit" class="btn_search" value="Search"> </div> </div> </form> </div> </div> <div class="row mt-3"> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Commenced</strong> in January 2007</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Frequency:</strong> Monthly</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Edition:</strong> International</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Paper Count:</strong> 1581</div> </div> </div> </div> <h1 class="mt-3 mb-3 text-center" style="font-size:1.6rem;">Search results for: invasive breast carcinoma (IBC)</h1> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1581</span> Patterns of Malignant and Benign Breast Lesions in Hail Region: A Retrospective Study at King Khalid Hospital</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Laila%20Seada">Laila Seada</a>, <a href="https://publications.waset.org/abstracts/search?q=Ashraf%20Ibrahim"> Ashraf Ibrahim</a>, <a href="https://publications.waset.org/abstracts/search?q=Amjad%20Al%20Shammari"> Amjad Al Shammari</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background and Objectives: Breast carcinoma is the most common cancer of females in Hail region, accounting for 31% of all diagnosed cancer cases followed by thyroid carcinoma (25%) and colorectal carcinoma (13%). Methods: In the present retrospective study, all cases of breast lesions received at the histopathology department in King Khalid Hospital, Hail, during the period from May 2011 to April 2016 have been retrieved from department files. For all cases, a trucut biopsy, lumpectomy, or modified radical mastectomy was available for histopathologic diagnosis, while 105/140 (75%) had, as well, preoperative fine needle aspirates (FNA). Results: 49 cases out of 140 (35%) breast lesions were carcinomas: 44/49 (89.75%) was invasive ductal, 2/49(4.1%) invasive lobular carcinomas, 1/49(2.05%) intracystic low grade papillary carcinoma and 2/49 (4.1%) ductal carcinoma in situ (DCIS). Mean age for malignant cases was 45.06 (+/-10.58): 32.6% were below the age of 40 and 30.6 below 50 years, 18.3% below 60 and 16.3% below 70 years. For the benign group, mean age was 32.52 (+/10.5) years. Benign lesions were in order of frequency: 34 fibroadenomas, 14 fibrocystic disease, 12 chronic mastitis, five granulomatous mastitis, three intraductal papillomas, and three benign phyllodes tumor. Tubular adenoma, lipoma, skin nevus, pilomatrixoma, and breast reduction specimens constituted the remaining specimens. Conclusion: Breast lesions are common in our series and invasive carcinoma accounts for more than 1/3<sup>rd</sup> of the lumps, with 63.2% incidence in pre-menopausal ladies, below the age of 50 years. FNA as a non-invasive procedure, proved to be an effective tool in diagnosing both benign and malignant/suspicious breast lumps and should continue to be used as a first assessment line of palpable breast masses. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=age%20incidence" title="age incidence">age incidence</a>, <a href="https://publications.waset.org/abstracts/search?q=breast%20carcinoma" title=" breast carcinoma"> breast carcinoma</a>, <a href="https://publications.waset.org/abstracts/search?q=fine%20needle%20aspiration" title=" fine needle aspiration"> fine needle aspiration</a>, <a href="https://publications.waset.org/abstracts/search?q=hail%20region" title=" hail region"> hail region</a> </p> <a href="https://publications.waset.org/abstracts/72605/patterns-of-malignant-and-benign-breast-lesions-in-hail-region-a-retrospective-study-at-king-khalid-hospital" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/72605.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">280</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1580</span> Impact of Lobular Carcinoma in situ on Local Recurrence in Breast Cancer Treated with Breast Conservation Therapy: A Systematic Review and Meta-Analysis</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Christopher%20G.%20Harris">Christopher G. Harris</a>, <a href="https://publications.waset.org/abstracts/search?q=Guy%20D.%20Eslick"> Guy D. Eslick</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Purpose: Lobular carcinoma in situ (LCIS) is a known risk factor for breast cancer of unclear significance when detected in association with invasive carcinoma. This meta-analysis aims to determine the impact of LCIS on local recurrence risk for individuals with breast cancer treated with breast conservation therapy to help guide appropriate treatment strategies. Methods: We identified relevant studies from five electronic databases. Studies were deemed suitable for inclusion where they compared patients with invasive breast cancer and concurrent LCIS to those with breast cancer alone, all patients underwent breast conservation therapy (lumpectomy with adjuvant radiation therapy), and local recurrence was evaluated. Recurrence data were pooled by use of a random effects model. Results: From 1488 citations screened by our search, 8 studies were deemed suitable for inclusion. These studies comprised of 908 cases and 10638 controls. Median follow-up time was 90 months. There was a significantly increased overall risk of local breast cancer recurrence for individuals with LCIS in association with breast cancer following breast conservation therapy [pOR 1.87; 95% CI 1.14-3.04; p = 0.012]. The risk of local recurrence was non-significantly increased at 5 [pOR 1.09; 95% CI 0.48-2.48; p = 0.828] and 10 years [pOR 1.90; 95% CI 0.89-4.06; p = 0.096]. Conclusions: Individuals with LCIS in association with invasive breast cancer have an increased risk of local recurrence following breast conservation therapy. This supports consideration of aggressive local control of LCIS by way of completion mastectomy or re-excision for certain high-risk patients. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=breast%20cancer" title="breast cancer">breast cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=breast%20conservation%20therapy" title=" breast conservation therapy"> breast conservation therapy</a>, <a href="https://publications.waset.org/abstracts/search?q=lobular%20carcinoma%20in%20situ" title=" lobular carcinoma in situ"> lobular carcinoma in situ</a>, <a href="https://publications.waset.org/abstracts/search?q=lobular%20neoplasia" title=" lobular neoplasia"> lobular neoplasia</a>, <a href="https://publications.waset.org/abstracts/search?q=local%20recurrence" title=" local recurrence"> local recurrence</a>, <a href="https://publications.waset.org/abstracts/search?q=meta-analysis" title=" meta-analysis"> meta-analysis</a> </p> <a href="https://publications.waset.org/abstracts/118522/impact-of-lobular-carcinoma-in-situ-on-local-recurrence-in-breast-cancer-treated-with-breast-conservation-therapy-a-systematic-review-and-meta-analysis" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/118522.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">160</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1579</span> An Audit on the Role of Sentinel Node Biopsy in High-Risk Ductal Carcinoma in Situ and Intracystic Papillary Carcinoma</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=M.%20Sulieman">M. Sulieman</a>, <a href="https://publications.waset.org/abstracts/search?q=H.%20Arabiyat"> H. Arabiyat</a>, <a href="https://publications.waset.org/abstracts/search?q=H.%20Ali"> H. Ali</a>, <a href="https://publications.waset.org/abstracts/search?q=K.%20Potiszil"> K. Potiszil</a>, <a href="https://publications.waset.org/abstracts/search?q=I.%20Abbas"> I. Abbas</a>, <a href="https://publications.waset.org/abstracts/search?q=R.%20English"> R. English</a>, <a href="https://publications.waset.org/abstracts/search?q=P.%20King"> P. King</a>, <a href="https://publications.waset.org/abstracts/search?q=I.%20Brown"> I. Brown</a>, <a href="https://publications.waset.org/abstracts/search?q=P.%20Drew"> P. Drew</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction: The incidence of breast ductal Carcinoma in Situ (DCIS) has been increasing; it currently represents up 20-25% of all breast carcinomas. Some aspects of DCIS management are still controversial, mainly due to the heterogeneity of its clinical presentation and of its biological and pathological characteristics. In DCIS, histological diagnosis obtained preoperatively, carries the risk of sampling error if the presence of invasive cancer is subsequently diagnosed. The mammographic extent over than 4–5 cm and the presence of architectural distortion, focal asymmetric density or mass on mammography are proven important risk factors of preoperative histological under staging. Intracystic papillary cancer (IPC) is a rare form of breast carcinoma. Despite being previously compared to DCIS it has been shown to present histologically with invasion of the basement membrane and even metastasis. SLNB – Carries the risk of associated comorbidity that should be considered when planning surgery for DCIS and IPC. Objectives: The aim of this Audit was to better define a ‘high risk’ group of patients with pre-op diagnosis of non-invasive cancer undergoing breast conserving surgery, who would benefit from sentinel node biopsy. Method: Retrospective data collection of all patients with ductal carcinoma in situ over 5 years. 636 patients identified, and after exclusion criteria applied: 394 patients were included. High risk defined as: Extensive micro-calcification >40mm OR any mass forming DCIS. IPC: Winpath search from for the term ‘papillary carcinoma’ in any breast specimen for 5 years duration;.29 patients were included in this group. Results: DCIS: 188 deemed high risk due to >40mm calcification or a mass forming (radiological or palpable) 61% of those had a mastectomy and 32% BCS. Overall, in that high-risk group - the number with invasive disease was 38%. Of those high-risk DCIS pts 85% had a SLN - 80% at the time of surgery and 5% at a second operation. For the BCS patients - 42% had SLN at time of surgery and 13% (8 patients) at a second operation. 15 (7.9%) pts in the high-risk group had a positive SLNB, 11 having a mastectomy and 4 having BCS. IPC: The provisional diagnosis of encysted papillary carcinoma is upgraded to an invasive carcinoma on final histology in around a third of cases. This has may have implications when deciding whether to offer sentinel node removal at the time of therapeutic surgery. Conclusions: We have defined a ‘high risk’ group of pts with pre-op diagnosis of non-invasive cancer undergoing BCS, who would benefit from SLNB at the time of the surgery. In patients with high-risk features; the risk of invasive disease is up to 40% but the risk of nodal involvement is approximately 8%. The risk of morbidity from SLN is up to about 5% especially the risk of lymphedema. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=breast%20ductal%20carcinoma%20in%20Situ%20%28DCIS%29" title="breast ductal carcinoma in Situ (DCIS)">breast ductal carcinoma in Situ (DCIS)</a>, <a href="https://publications.waset.org/abstracts/search?q=intracystic%20papillary%20carcinoma%20%28IPC%29" title=" intracystic papillary carcinoma (IPC)"> intracystic papillary carcinoma (IPC)</a>, <a href="https://publications.waset.org/abstracts/search?q=sentinel%20node%20biopsy%20%28SLNB%29" title=" sentinel node biopsy (SLNB)"> sentinel node biopsy (SLNB)</a>, <a href="https://publications.waset.org/abstracts/search?q=high-risk" title=" high-risk"> high-risk</a>, <a href="https://publications.waset.org/abstracts/search?q=non-invasive" title=" non-invasive"> non-invasive</a>, <a href="https://publications.waset.org/abstracts/search?q=cancer%20disease" title=" cancer disease"> cancer disease</a> </p> <a href="https://publications.waset.org/abstracts/153886/an-audit-on-the-role-of-sentinel-node-biopsy-in-high-risk-ductal-carcinoma-in-situ-and-intracystic-papillary-carcinoma" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/153886.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">111</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1578</span> Serum 25-Hydroxyvitamin D Levels in Korean Breast Cancer Patients</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Sung%20Yong%20Kim">Sung Yong Kim</a>, <a href="https://publications.waset.org/abstracts/search?q=Byung%20Joo%20Song"> Byung Joo Song</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: Circulating 25-hydroxyvitamin D (25(OH)D) levels has been considered to be inversely related to breast cancer development, recurrence risk, and mortality. Mean vitamin D levels in Korean population is lower than western countries due to higher incidence of lactose intolerance and lower exposure to sunlight. The purpose of this study was to assess incidence of 25(OH)D deficiency at diagnosis and after adjuvant chemotherapy and to investigate the correlation serum 25(OH)D levels with clinicopathologic features. Methods: From December 2011 to October 2012, 280 breast cancer patients seen at a single tertiary cancer center were enrolled. Serum 25(OH)D was measured at the time of surgery and after completion of adjuvant chemotherapy. Statistical analyses used chi-square test, Fisher's exact test, t-test, and ANOVA. Results: Mean serum 25(OH)D was 18.5 ng/ml. The 25(OH)D levels were deficient (<20 ng/ml) in 190 patients (67.9%), insufficient (20-29 ng/ml) in 51 patients(18.2%), and sufficient (30-150 ng/ml) in 39 patients(13.9%). A notable decrease in 25(OH)D concentration was observed(p<0.001) after chemotherapy but was not related to chemotherapy regimens. It was found significant lower 25(OH)D levels at winter season(from October to March, p=0.030). Subjects with invasive carcinoma (IDC or ILC) had significantly lower circulating levels of 25(OH)D than those with ductal carcinoma in situ(DCIS) (p=0.010). Patients with larger tumor size tends to have lower serum 25(OH)D but there were no statistical significance. Conclusions: Most of the breast cancer patients showed deficient or insufficient serum 25(OH)D concentration. Incidence of vitamin D deficiency was higher in invasive carcinoma than DCIS. Serum 25(OH)D levels were decreased after chemotherapy. Consideration should be given to the supplement of vitamin D to those patients. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=breast%20neoplasms" title="breast neoplasms">breast neoplasms</a>, <a href="https://publications.waset.org/abstracts/search?q=vitamin%20D" title=" vitamin D"> vitamin D</a>, <a href="https://publications.waset.org/abstracts/search?q=Korean%20population" title=" Korean population"> Korean population</a>, <a href="https://publications.waset.org/abstracts/search?q=breast%20cancer" title=" breast cancer"> breast cancer</a> </p> <a href="https://publications.waset.org/abstracts/16326/serum-25-hydroxyvitamin-d-levels-in-korean-breast-cancer-patients" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/16326.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">416</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1577</span> Metastatic Invasive Lobular Cancer Presenting as a Cervical Polyp</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Sally%20Shepherd">Sally Shepherd</a>, <a href="https://publications.waset.org/abstracts/search?q=Craig%20Murphy"> Craig Murphy</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction: The uterus or cervix are unusual locations as metastatic sites for cancers. It is further unusual for it to be a site of metastasis, whilst the primary malignancy remains occult. Case Report: A 63-year-old female with three months of altered bowel habits underwent a CT scan of the abdomen and pelvis, revealing a bulky uterus and left ovary, nonspecific colonic thickening, and diffuse peritoneal changes. She underwent colposcopy, which revealed a large endocervical polyp that was excised, revealing strongly hormone-positive metastatic invasive lobular breast cancer. She subsequently underwent a PET scan, which showed moderately diffuse activity in the cervix and left adnexa. Breast examination was unremarkable, and screening mammography, ultrasound, and MRI of the breast did not identify any lesions. Her blood tests revealed a Ca 15-3 of 934, CA-125 of 220, and CEA of 27. She was commenced on letrozole and ribociclib with an improvement in her symptoms. Conclusion: It is rare for occult breast cancer to be established and diagnosed by pelvic imaging and biopsy. Suspicion of uterine or cervical metastasis should be heightened in patients with an active or past history of breast cancer. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=occult%20breast%20cancer" title="occult breast cancer">occult breast cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=cervical%20metastasis" title=" cervical metastasis"> cervical metastasis</a>, <a href="https://publications.waset.org/abstracts/search?q=invasive%20lobular%20carcinoma" title=" invasive lobular carcinoma"> invasive lobular carcinoma</a>, <a href="https://publications.waset.org/abstracts/search?q=metastasis" title=" metastasis"> metastasis</a> </p> <a href="https://publications.waset.org/abstracts/131927/metastatic-invasive-lobular-cancer-presenting-as-a-cervical-polyp" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/131927.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">124</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1576</span> TP53 Mutations in Molecular Subtypes of Breast Cancer in Young Pakistani Patients</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Nadia%20Naseem">Nadia Naseem</a>, <a href="https://publications.waset.org/abstracts/search?q=Farwa%20Batool"> Farwa Batool</a>, <a href="https://publications.waset.org/abstracts/search?q=Nasir%20Mehmood"> Nasir Mehmood</a>, <a href="https://publications.waset.org/abstracts/search?q=AbdulHannan%20Nagi"> AbdulHannan Nagi</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: The incidence and mortality of breast cancer vary significantly in geographically distinct populations. In Pakistan, breast cancer has shown an increase in incidence in young females and is characterized by more aggressive behavior. The tumor suppressor TP53 gene is a crucial genetic factor that plays a significant role in breast carcinogenesis. This study investigated the TP53 mutations in molecular subtypes of both nodes negative and positive breast cancer in young Pakistani patients. Material and Methods: p53, Estrogen Receptor (ER), Progesterone Receptor (PR), Her-2 neu and Ki 67 expressions were analyzed immunohistochemically in a series of 75 node negative (A) and 75 node positive (B) young (aged: 19-40 years) breast cancer patients diagnosed between 2014 to 2017 at two leading hospitals of Punjab, Pakistan. Tumor tissue specimens and peripheral blood samples were examined for TP53 mutations by direct sequencing of the gene (exons 4-9). The relation of TP53 mutations to these markers and clinicopathological data was investigated. Results: Mean age of the patients was 32.4 + 9.1 SD. Invasive breast carcinoma was the most frequent histological variant (A=92%, B=94.6%). Grade 3 carcinoma was the commonest grade (A=72%, B=81.3%). Triple negative cases (ER-, PR-, Her-2) formed most of the molecular subtypes (A=44%, B=50.6%). A total of 17.2% (A: 6.6%, B: 10.6%) patients showed TP53 mutations. Mutations were significantly more frequent in triple negative cases (A: 74.8%, B: 62.2%) compared to HER2-positive patients (P < 0.0001). In the multivariate analysis of the whole patient group, the independent prognosticator were triple negative cases (P=0.021), TP53 overexpression by IHC (P=0.001) and advanced-stage disease (P=0.007). No statistically significant correlation between TP53 mutations and clinicopathological parameters was found (P < 0.05). Conclusions: It is concluded that TP53 mutations are infrequently present in breast carcinoma of young Pakistani population and there was no significant correlation between p53 mutation and early onset disease. Immunohistochemically detected TP53 expression in our resource-constrained to set up can be beneficial in predicting mutations at the younger age in our population. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=immunohistochemistry%20%28IHC%29" title="immunohistochemistry (IHC)">immunohistochemistry (IHC)</a>, <a href="https://publications.waset.org/abstracts/search?q=invasive%20breast%20carcinoma%20%28IBC%29" title=" invasive breast carcinoma (IBC)"> invasive breast carcinoma (IBC)</a>, <a href="https://publications.waset.org/abstracts/search?q=Pakistan" title=" Pakistan"> Pakistan</a>, <a href="https://publications.waset.org/abstracts/search?q=TP53" title=" TP53"> TP53</a> </p> <a href="https://publications.waset.org/abstracts/89221/tp53-mutations-in-molecular-subtypes-of-breast-cancer-in-young-pakistani-patients" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/89221.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">158</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1575</span> Tumor-Biological Characteristics of Invasive Lobular Carcinoma</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Sabine%20Danzinger">Sabine Danzinger</a>, <a href="https://publications.waset.org/abstracts/search?q=Nora%20Hielscher"> Nora Hielscher</a>, <a href="https://publications.waset.org/abstracts/search?q=Miriam%20Izso"> Miriam Izso</a>, <a href="https://publications.waset.org/abstracts/search?q=Johanna%20Metzler"> Johanna Metzler</a>, <a href="https://publications.waset.org/abstracts/search?q=Carmen%20Trinkl"> Carmen Trinkl</a>, <a href="https://publications.waset.org/abstracts/search?q=Christian%20Pfeifer"> Christian Pfeifer</a>, <a href="https://publications.waset.org/abstracts/search?q=Kristina%20Tendl-Schulz"> Kristina Tendl-Schulz</a>, <a href="https://publications.waset.org/abstracts/search?q=Christian%20F.%20Singer"> Christian F. Singer</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The objective of this study is to analyze the characteristics of invasive lobular carcinoma (ILC) compared with invasive ductal carcinoma (IDC) and to investigate the impact of histology on axillary lymph node (ALN) involvement in luminal A subtype tumors. Methods: We retrospectively analyzed patients diagnosed with ILC or IDC from 2012 to 2016 who underwent surgery. Patients constituted 493 primary early breast cancer cases (82 ILC; 411 IDC). Results: Compared with IDC, ILC tumors were significantly more likely to be grade 2, estrogen receptor- (ER) positive (þ), have a lower proliferation rate (Ki67 <14%), and a higher patholog- ical T stage (pT2–4). The luminal A subtype was significantly more common in ILC compared with IDC. In a multivariate regression model, grade 2, ERþ, progesterone receptor-positive, pT2, and pT3 were significantly associated with ILC. Additionally, with the luminal A subtype, ALN involvement (pathological node stage (pN)1–3) was significantly more frequent with ILC versus IDC. Conclusions: Our data suggests that grade 2, positive hormone receptor status, and higher pathological T stage are associated with ILC. With the luminal A subtype, ALN involvement was more frequent with ILC versus IDC. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=breast%20cancer" title="breast cancer">breast cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=lobular%20histology" title=" lobular histology"> lobular histology</a>, <a href="https://publications.waset.org/abstracts/search?q=tumor%20biology" title=" tumor biology"> tumor biology</a>, <a href="https://publications.waset.org/abstracts/search?q=hormone%20receptor" title=" hormone receptor"> hormone receptor</a>, <a href="https://publications.waset.org/abstracts/search?q=ki67" title=" ki67"> ki67</a> </p> <a href="https://publications.waset.org/abstracts/193830/tumor-biological-characteristics-of-invasive-lobular-carcinoma" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/193830.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">10</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1574</span> HLA-G, a Neglected Immunosuppressive Checkpoint for Breast Cancer Immunotherapy</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Xian-Peng%20Jiang">Xian-Peng Jiang</a>, <a href="https://publications.waset.org/abstracts/search?q=Catherine%20C.%20Baucom"> Catherine C. Baucom</a>, <a href="https://publications.waset.org/abstracts/search?q=Toby%20Jiang"> Toby Jiang</a>, <a href="https://publications.waset.org/abstracts/search?q=Robert%20L.%20Elliott"> Robert L. Elliott</a> </p> <p class="card-text"><strong>Abstract:</strong></p> HLA-G binds to the inhibitory receptors of uterine NK cells and plays an important role in protection of fetal cells from maternal NK lysis. HLA-G also mediates tumor escape, but the immunosuppressive role is often neglected. These studies have focused on the examination of HLA-G expression in human breast carcinoma and HLA-G immunosuppressive role in NK cytolysis. We examined HLA-G expression in breast cell lines by real time PCR, ELISA and immunofluorescent staining. We treated the breast cancer cell lines with anti-human HLA-G antibody or progesterone. Then, NK cytolysis was measured by using MTT assay. We find that breast carcinoma cell lines increase the expression of HLA-G mRNA and protein, compared to normal cells. Blocking HLA-G of the breast cancer cells by the antibody increases NK cytolysis. Progesterone upregulates HLA-G mRNA and protein of human breast cancer cell lines. The increased HLA-G expression suppresses NK cytolysis. In summary, human breast carcinoma overexpress HLA-G immunosuppressive molecules. Blocking HLA-G protein by antibody improves NK cytolysis. In contrast, upregulation of HLA-G expression by progesterone impairs NK cytolytic function. Thus, HLA-G is a new immunosuppressive checkpoint and potential cancer immunotherapeutic target. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=HLA-G" title="HLA-G">HLA-G</a>, <a href="https://publications.waset.org/abstracts/search?q=Breast%20carcinoma" title=" Breast carcinoma"> Breast carcinoma</a>, <a href="https://publications.waset.org/abstracts/search?q=NK%20cells" title=" NK cells"> NK cells</a>, <a href="https://publications.waset.org/abstracts/search?q=Immunosuppressive%20checkpoint" title=" Immunosuppressive checkpoint"> Immunosuppressive checkpoint</a> </p> <a href="https://publications.waset.org/abstracts/161283/hla-g-a-neglected-immunosuppressive-checkpoint-for-breast-cancer-immunotherapy" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/161283.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">89</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1573</span> The Role of Surgery to Remove the Primary Tumor in Patients with Metastatic Breast Cancer</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=A.%20D.%20Zikiryahodjaev">A. D. Zikiryahodjaev</a>, <a href="https://publications.waset.org/abstracts/search?q=L.%20V.%20Bolotina"> L. V. Bolotina</a>, <a href="https://publications.waset.org/abstracts/search?q=A.%20S.%20Sukhotko"> A. S. Sukhotko</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Purpose. To evaluate the expediency and timeliness of performance of surgical treatment as a component of multi-therapy treatment of patients with stage IV breast cancers. Materials and Methods. This investigation comparatively analyzed the results of complex treatment with or without surgery in patients with metastatic breast cancer. We analyzed retrospectively treatment experience of 196 patients with generalized breast cancer in the department of oncology and breast reconstructive surgery of P.A. Herzen Moscow Cancer Research Institute from 2000 to 2012. The average age was (58±1,1) years. Invasive ductul carcinoma was verified in128 patients (65,3%), invasive lobular carcinoma-33 (16,8%), complex form - 19 (9,7%). Complex palliative care involving drug and radiation therapies was performed in two patient groups. The first group includes 124 patients who underwent surgical intervention as complex treatment, the second group includes 72 patients with only medical therapy. Standard systemic therapy was given to all patients. Results. Overall, 3-and 5-year survival in fist group was 43,8 and 21%, in second - 15,1 and 9,3% respectively [p=0,00002 log-rank]. Median survival in patients with surgical treatment composed 32 months, in patients with only systemic therapy-21. The factors having influencing an influence on the prognosis and the quality of life outcomes for of patients with generalized breast cancer were are also studied: hormone-dependent tumor, Her2/neu hyper-expression, reproductive function status (age, menopause existence). Conclusion.Removing primary breast tumor in patients with generalized breast cancer improve long-term outcomes. Three- and five-year survival increased by 28,7 and 16,3% respectively, and median survival–for 11 months. These patients may benefit from resection of the breast tumor. One explanation for the effect of this resection is that reducing the tumor load influences metastatic growth. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=breast%20cancer" title="breast cancer">breast cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=combination%20therapy" title=" combination therapy"> combination therapy</a>, <a href="https://publications.waset.org/abstracts/search?q=factors%20of%20prognosis" title=" factors of prognosis"> factors of prognosis</a>, <a href="https://publications.waset.org/abstracts/search?q=primary%20tumor" title=" primary tumor"> primary tumor</a> </p> <a href="https://publications.waset.org/abstracts/20501/the-role-of-surgery-to-remove-the-primary-tumor-in-patients-with-metastatic-breast-cancer" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/20501.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">416</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1572</span> Management of Gastrointestinal Metastasis of Invasive Lobular Carcinoma</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Sally%20Shepherd">Sally Shepherd</a>, <a href="https://publications.waset.org/abstracts/search?q=Richard%20De%20Boer"> Richard De Boer</a>, <a href="https://publications.waset.org/abstracts/search?q=Craig%20Murphy"> Craig Murphy</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: Invasive lobular carcinoma (ILC) can metastasize to atypical sites within the peritoneal cavity, gastrointestinal, or genitourinary tract. Management varies depending on the symptom presentation, extent of disease burden, particularly if the primary disease is occult, and patient wishes. Case Series: 6 patients presented with general surgical presentations of ILC, including incomplete large bowel obstruction, cholecystitis, persistent lower abdominal pain, and faecal incontinence. 3 were diagnosed with their primary and metastatic disease in the same presentation, whilst 3 patients developed metastasis from 5 to 8 years post primary diagnosis of ILC. Management included resection of the metastasis (laparoscopic cholecystectomy), excision of the primary (mastectomy and axillary clearance), followed by a combination of aromatase inhibitors, biologic therapy, and chemotherapy. Survival post diagnosis of metastasis ranged from 3 weeks to 7 years. Conclusion: Metastatic ILC must be considered with any gastrointestinal or genitourinary symptoms in patients with a current or past history of ILC. Management may not be straightforward to chemotherapy if the acute pathology is resulting in a surgically resectable disease. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=breast%20cancer" title="breast cancer">breast cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=gastrointestinal%20metastasis" title=" gastrointestinal metastasis"> gastrointestinal metastasis</a>, <a href="https://publications.waset.org/abstracts/search?q=invasive%20lobular%20carcinoma" title=" invasive lobular carcinoma"> invasive lobular carcinoma</a>, <a href="https://publications.waset.org/abstracts/search?q=metastasis" title=" metastasis"> metastasis</a> </p> <a href="https://publications.waset.org/abstracts/131926/management-of-gastrointestinal-metastasis-of-invasive-lobular-carcinoma" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/131926.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">148</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1571</span> Case Report on ‘Primary Adenocarcinoma of Aberrant HER2+ Anogenital Mammary-like Glands in a Male'</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Shivani%20Kuttuva">Shivani Kuttuva</a>, <a href="https://publications.waset.org/abstracts/search?q=James%20Sampson"> James Sampson</a>, <a href="https://publications.waset.org/abstracts/search?q=Timothy%20Simmons"> Timothy Simmons</a>, <a href="https://publications.waset.org/abstracts/search?q=Vinayak%20Thattaruparambil"> Vinayak Thattaruparambil</a>, <a href="https://publications.waset.org/abstracts/search?q=Holly%20Burton"> Holly Burton</a>, <a href="https://publications.waset.org/abstracts/search?q=Peter%20Coyne"> Peter Coyne</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Anogenital mammary-like glands were established to be embryological remnants of breast tissue due to failed resolution of the ectodermal mammary ridge. However, recent studies are now considering this to represent normal constituents of the anogenital area with histological resemblance to the orthotopic breast tissue with multiple benign and malignant lesions arising from it. The incidence of the above has been predominant in females in the vulval region. Due to the paucity of cases reported in men, this poses a diagnostic and therapeutic challenge resulting in a delay in treatment and, thereby, poor outcomes. Our patient presented to the dermatology clinic with an itchy, purplish lesion in the peri-anal region which, on punch biopsy, was diagnosed to be Extra-mammary Paget’s disease and taken up for Wide local excision. Immunochemically, staining was positive for HER2, ER and Cytokeratin 7, keeping with the presence of actual breast tissue with no primary breast carcinoma. Due to the invasive nature of the disease, he required Abdominoperineal resection with flap reconstruction. Despite complete surgical clearance and adjuvant radiotherapy, the disease progressed to adjacent inguinal and obturator lymph nodes with origin resembling anogenital type mammary glands but histology negative for hormonal receptors of the breast. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=anogenital%20mammary-like%20glands" title="anogenital mammary-like glands">anogenital mammary-like glands</a>, <a href="https://publications.waset.org/abstracts/search?q=abdominoperineal%20resection" title=" abdominoperineal resection"> abdominoperineal resection</a>, <a href="https://publications.waset.org/abstracts/search?q=ectopic%20breast%20tissue" title=" ectopic breast tissue"> ectopic breast tissue</a>, <a href="https://publications.waset.org/abstracts/search?q=ectopic%20male%20breast%20carcinoma" title=" ectopic male breast carcinoma"> ectopic male breast carcinoma</a>, <a href="https://publications.waset.org/abstracts/search?q=peri-anal%20skin%20lesion" title=" peri-anal skin lesion"> peri-anal skin lesion</a> </p> <a href="https://publications.waset.org/abstracts/165237/case-report-on-primary-adenocarcinoma-of-aberrant-her2-anogenital-mammary-like-glands-in-a-male" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/165237.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">80</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1570</span> Clinical Outcomes For Patients Diagnosed With DCIS Through The Breast Screening Programme</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Aisling%20Eves">Aisling Eves</a>, <a href="https://publications.waset.org/abstracts/search?q=Andrew%20Pieri"> Andrew Pieri</a>, <a href="https://publications.waset.org/abstracts/search?q=Ross%20McLean"> Ross McLean</a>, <a href="https://publications.waset.org/abstracts/search?q=Nerys%20Forester"> Nerys Forester</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: DCIS accounts for 20% of malignancies diagnosed by the breast screening programme and is primarily managed by surgical excision. There is variable guidance on defining excision margins, and adjuvant treatments vary widely. This study aimed to investigate the clinical outcomes for patients following surgical excision of small volume DCIS. Methods: This single-centreretrospective cohort study of 101 consecutive breast screened patients diagnosed with DCIS who underwent surgical excision. All patients diagnosed with DCIS had radiological abnormalities <15mm. Clinical, radiological, and histological data were collected from patients who had been diagnosed within a 5 year period, and ASCO guidelines for margin involvement of <2mm was used to guide the need for re-excision. Outcomes included re-excision rates, radiotherapy usage, and the presence of invasive cancer. Results: Breast conservation surgery was performed in 94.1% (n=95). Following surgical excision, 74(73.27%)patients had complete DCIS excision (>2mm margin), 4(4.0%) had margins 1-2mm, and 17(16.84%)had margins <1mm. The median size of DCIS in the specimen sample was 4mm. In 86% of patients with involved margins (n=18), the mammogram underestimated the DCIS size by a median of 12.5mm (range: 1-42mm). Of the patients with involved margins, 11(10.9%)had a re-excision, and 6 of these (50%) required two re-excisions to completely excise the DCIS. Post-operative radiotherapy was provided to 53(52.48%)patients. Four (3.97%) patients were found to have invasive ductal carcinoma on surgical excision, which was not present on core biopsy – all had high-grade DCIS. Recurrence of DCIS was seen in the same site during follow-up in 1 patient (1%), 1 year after their first DCIS diagnosis. Conclusion: Breast conservation surgery is safe in patients with DCIS, with low rates of re-excision, recurrence, and upstaging to invasive cancer. Furthermore, the median size of DCIS found in the specimens of patients who had DCIS fully removed in surgery was low, suggesting it may be possible that total removal through VAE was possible for these patients. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=surgical%20excision" title="surgical excision">surgical excision</a>, <a href="https://publications.waset.org/abstracts/search?q=breast%20conservation%20surgery" title=" breast conservation surgery"> breast conservation surgery</a>, <a href="https://publications.waset.org/abstracts/search?q=DCIS" title=" DCIS"> DCIS</a>, <a href="https://publications.waset.org/abstracts/search?q=Re-excision" title=" Re-excision"> Re-excision</a>, <a href="https://publications.waset.org/abstracts/search?q=radiotherapy" title=" radiotherapy"> radiotherapy</a>, <a href="https://publications.waset.org/abstracts/search?q=invasive%20cancer" title=" invasive cancer"> invasive cancer</a> </p> <a href="https://publications.waset.org/abstracts/146028/clinical-outcomes-for-patients-diagnosed-with-dcis-through-the-breast-screening-programme" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/146028.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">133</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1569</span> An Audit of Local Guidance Compliance For Stereotactic Core Biopsy For DCIS In The Breast Screening Programme</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Aisling%20Eves">Aisling Eves</a>, <a href="https://publications.waset.org/abstracts/search?q=Andrew%20Pieri"> Andrew Pieri</a>, <a href="https://publications.waset.org/abstracts/search?q=Ross%20McLean"> Ross McLean</a>, <a href="https://publications.waset.org/abstracts/search?q=Nerys%20Forester"> Nerys Forester</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: The breast unit local guideline recommends that 12 cores should be used in a stereotactic-guided biopsy to diagnose DCIS. Twelve cores are regarded to provide good diagnostic value without removing more breast tissue than necessary. This study aimed to determine compliance with guidelines and investigated how the number of cores impacted upon the re-excision rate and size discrepancies. Methods: This single-centre retrospective cohort study of 72 consecutive breast screened patients with <15mm DCIS on radiological report underwent stereotactic-guided core biopsy and subsequent surgical excision. Clinical, radiological, and histological data were collected over 5 years, and ASCO guidelines for margin involvement of <2mm was used to guide the need for re-excision. Results: Forty-six (63.9%) patients had <12 cores taken, and 26 (36.1%) patients had ≥12 cores taken. Only six (8.3%) patients had 12 cores taken in their stereotactic biopsy. Incomplete surgical excision was seen in 17 patients overall (23.6%), and of these patients, twelve (70.6%) had fewer than 12 cores taken (p=0.55 for the difference between groups). Mammogram and biopsy underestimated the size of the DCIS in this subgroup by a median of 15mm (range: 6-135mm). Re-excision was required in 9 patients (12.5%), and five patients (6.9%) were found to have invasive ductal carcinoma on excision (80% had <12 cores, p=0.43). Discussion: There is poor compliance with the breast unit local guidelines and higher rates of re-excision in patients who did not have ≥12 cores taken. Taking ≥12 cores resulted in fewer missed invasive cancers lower incomplete excision and re-excision rates. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=stereotactic%20core%20biopsy" title="stereotactic core biopsy">stereotactic core biopsy</a>, <a href="https://publications.waset.org/abstracts/search?q=DCIS" title=" DCIS"> DCIS</a>, <a href="https://publications.waset.org/abstracts/search?q=breast%20screening" title=" breast screening"> breast screening</a>, <a href="https://publications.waset.org/abstracts/search?q=Re-excision%20rates" title=" Re-excision rates"> Re-excision rates</a>, <a href="https://publications.waset.org/abstracts/search?q=core%20biopsy" title=" core biopsy"> core biopsy</a> </p> <a href="https://publications.waset.org/abstracts/146029/an-audit-of-local-guidance-compliance-for-stereotactic-core-biopsy-for-dcis-in-the-breast-screening-programme" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/146029.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">128</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1568</span> Discriminant Function Based on Circulating Tumor Cells for Accurate Diagnosis of Metastatic Breast Cancer</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Hatem%20A.%20El-Mezayen">Hatem A. El-Mezayen</a>, <a href="https://publications.waset.org/abstracts/search?q=Ahmed%20Abdelmajeed"> Ahmed Abdelmajeed</a>, <a href="https://publications.waset.org/abstracts/search?q=Fatehya%20Metwally"> Fatehya Metwally</a>, <a href="https://publications.waset.org/abstracts/search?q=Usama%20Elsaly"> Usama Elsaly</a>, <a href="https://publications.waset.org/abstracts/search?q=Salwa%20Atef"> Salwa Atef</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Tumor metastasis involves the dissemination of malignant cells into the basement membrane and vascular system contributes to the circulating pool of these markers. In this context our aim has been focused on development of a non-invasive. Circulating tumor cells (CTCs) represent a unique liquid biopsy carrying comprehensive biological information of the primary tumor. Herein, we sought to develop a novel score based on the combination of the most significant CTCs biomarkers with and routine laboratory tests for accurate detection of metastatic breast cancer. Methods: Cytokeratin 18 (CK18), Cytokeratin 19 (CK19), and CA15.3 were assayed in metastatic breast cancer (MBC) patients (75), non-MBC patients (50) and healthy control (20). Results: Areas under receiving operating curve (AUCs) were calculated and used for construction on novel score. A novel score named MBC-CTCs = CA15.3 (U/L) × 0.08 + CK 18 % × 2.9 + CK19 × 3.1– 510. That function correctly classified 87% of metastatic breast cancer at cut-off value = 0.55. (i.e great than 0.55 indicates patients with metastatic breast cancer and less than 0.55 indicates patients with non-metastatic breast cancer). Conclusion: MBC-CTCs is a novel, non-invasive and simple can applied to discriminate patients with metastatic breast cancer. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=metastatic%20breast%20cancer" title="metastatic breast cancer">metastatic breast cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=circulating%20tumor%20cells" title=" circulating tumor cells"> circulating tumor cells</a>, <a href="https://publications.waset.org/abstracts/search?q=cytokeratin" title=" cytokeratin"> cytokeratin</a>, <a href="https://publications.waset.org/abstracts/search?q=EpiCam" title=" EpiCam"> EpiCam</a> </p> <a href="https://publications.waset.org/abstracts/146716/discriminant-function-based-on-circulating-tumor-cells-for-accurate-diagnosis-of-metastatic-breast-cancer" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/146716.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">214</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1567</span> Pre-Malignant Breast Lesions, Methods of Treatment and Outcome</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Ahmed%20Mostafa">Ahmed Mostafa</a>, <a href="https://publications.waset.org/abstracts/search?q=Mohamed%20Mahmoud"> Mohamed Mahmoud</a>, <a href="https://publications.waset.org/abstracts/search?q=Nesreen%20H.%20Hafez"> Nesreen H. Hafez</a>, <a href="https://publications.waset.org/abstracts/search?q=Mohamed%20Fahim"> Mohamed Fahim</a> </p> <p class="card-text"><strong>Abstract:</strong></p> This retrospective study includes 60 patients with pre-invasive breast cancer. Aim of the study: Evaluation of premalignant lesions of the breast (DCIS), different treatment methods and outcome. Patients and methods: 60 patients with DCIS were studied from the period between 2005 to 2012, for 38 patients the primary surgical method was wide local resection (WLE) (63.3%) and the other cases (22 patients, 36.7%) had mastectomy, fourteen cases from those who underwent local excision received radiotherapy, while no adjuvant radiotherapy was given for those who underwent mastectomy. In case of hormonal receptor positive DCIS lesions hormonal treatment (Tamoxifen) was given after local control. Results: No difference in overall survival between mastectomy & breast conserving therapy (wide local excision and adjuvant radiotherapy), however local recurrence rate is higher in case of breast conserving therapy, also no role of Axillary evacuation in case of DCIS. The use of hormonal therapy decreases the incidence of local recurrence by about 98%. Conclusion: The main management of DCIS is local treatment (wide local excision and radiotherapy) with hormonal treatment in case of hormone receptor positive lesions. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=ductal%20carcinoma%20in%20situ" title="ductal carcinoma in situ">ductal carcinoma in situ</a>, <a href="https://publications.waset.org/abstracts/search?q=surgical%20treatment" title=" surgical treatment"> surgical treatment</a>, <a href="https://publications.waset.org/abstracts/search?q=radiotherapy" title=" radiotherapy"> radiotherapy</a>, <a href="https://publications.waset.org/abstracts/search?q=breast%20conserving%20therapy" title=" breast conserving therapy"> breast conserving therapy</a>, <a href="https://publications.waset.org/abstracts/search?q=hormonal%20treatment" title=" hormonal treatment"> hormonal treatment</a> </p> <a href="https://publications.waset.org/abstracts/47658/pre-malignant-breast-lesions-methods-of-treatment-and-outcome" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/47658.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">322</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1566</span> Comparison of 18F-FDG and 11C-Methionine PET-CT for Assessment of Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Carcinoma</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Sonia%20Mahajan%20Dinesh">Sonia Mahajan Dinesh</a>, <a href="https://publications.waset.org/abstracts/search?q=Anant%20Dinesh"> Anant Dinesh</a>, <a href="https://publications.waset.org/abstracts/search?q=Madhavi%20Tripathi"> Madhavi Tripathi</a>, <a href="https://publications.waset.org/abstracts/search?q=Vinod%20Kumar%20Ramteke"> Vinod Kumar Ramteke</a>, <a href="https://publications.waset.org/abstracts/search?q=Rajnish%20Sharma"> Rajnish Sharma</a>, <a href="https://publications.waset.org/abstracts/search?q=Anupam%20Mondal"> Anupam Mondal</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: Neo-adjuvant chemotherapy plays an important role in treatment of breast cancer by decreasing the tumour load and it offers an opportunity to evaluate response of primary tumour to chemotherapy. Standard anatomical imaging modalities are unable to accurately reflect the response to chemotherapy until several cycles of drug treatment have been completed. Metabolic imaging using tracers like 18F-fluorodeoxyglucose (FDG) as a marker of glucose metabolism or amino acid tracers like L-methyl-11C methionine (MET) have potential role for the measurement of treatment response. In this study, our objective was to compare these two PET tracers for assessment of response to neoadjuvant chemotherapy, in locally advanced breast carcinoma. Methods: In our prospective study, 20 female patients with histology proven locally advanced breast carcinoma underwent PET-CT imaging using FDG and MET before and after three cycles of neoadjuvant chemotherapy (CAF regimen). Thereafter, all patients were taken for MRM and the resected specimen was sent for histo-pathological analysis. Tumour response to the neoadjuvant chemotherapy was evaluated by PET-CT imaging using PERCIST criteria and correlated with histological results. Responses calculated were compared for statistical significance using paired t- test. Results: Mean SUVmax for primary lesion in FDG PET and MET PET was 15.88±11.12 and 5.01±2.14 respectively (p<0.001) and for axillary lymph nodes was 7.61±7.31 and 2.75±2.27 respectively (p=0.001). Statistically significant response in primary tumour and axilla was noted on both FDG and MET PET after three cycles of NAC. Complete response in primary tumour was seen in only 1 patient in FDG and 7 patients in MET PET (p=0.001) whereas there was no histological complete resolution of tumor in any patient. Response to therapy in axillary nodes noted on both PET scans were similar (p=0.45) and correlated well with histological findings. Conclusions: For the primary breast tumour, FDG PET has a higher sensitivity and accuracy than MET PET and for axilla both have comparable sensitivity and specificity. FDG PET shows higher target to background ratios so response is better predicted for primary breast tumour and axilla. Also, FDG-PET is widely available and has the advantage of a whole body evaluation in one study. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=11C-methionine" title="11C-methionine">11C-methionine</a>, <a href="https://publications.waset.org/abstracts/search?q=18F-FDG" title=" 18F-FDG"> 18F-FDG</a>, <a href="https://publications.waset.org/abstracts/search?q=breast%20carcinoma" title=" breast carcinoma"> breast carcinoma</a>, <a href="https://publications.waset.org/abstracts/search?q=neoadjuvant%20chemotherapy" title=" neoadjuvant chemotherapy"> neoadjuvant chemotherapy</a> </p> <a href="https://publications.waset.org/abstracts/1987/comparison-of-18f-fdg-and-11c-methionine-pet-ct-for-assessment-of-response-to-neoadjuvant-chemotherapy-in-locally-advanced-breast-carcinoma" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/1987.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">510</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1565</span> Evaluation of Tumor-Infiltrating Lymphocytes in Breast Carcinoma: Correlation with Molecular Subtypes and Clinicopathological Parameters</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Arundhathi%20S.">Arundhathi S.</a>, <a href="https://publications.waset.org/abstracts/search?q=Poongodi%20R."> Poongodi R.</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Tumor-infiltrating lymphocytes (TILs) are indicative of the local immune response against tumor proliferation and metastasis. Emerging as a significant marker of immune reactivity, TILs are utilized to evaluate prognostic outcomes across various malignancies, including colon, ovarian, lung, bladder, and breast cancers. In breast cancer (BC), TILs are particularly relevant for assessing tumor response to therapy in both adjuvant and neoadjuvant settings, with a prominent role in triple-negative breast cancer (TNBC), where they have been associated with improved outcomes. As such, TILs are recognized as an independent marker of favorable prognosis in several tumor types, underscoring their potential as a tool in personalized cancer therapy. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=breast%20cancer" title="breast cancer">breast cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=intratumoral%20TIL" title=" intratumoral TIL"> intratumoral TIL</a>, <a href="https://publications.waset.org/abstracts/search?q=stromal%20TIL" title=" stromal TIL"> stromal TIL</a>, <a href="https://publications.waset.org/abstracts/search?q=tumor%20infiltrating%20lymphocytes" title=" tumor infiltrating lymphocytes"> tumor infiltrating lymphocytes</a> </p> <a href="https://publications.waset.org/abstracts/194529/evaluation-of-tumor-infiltrating-lymphocytes-in-breast-carcinoma-correlation-with-molecular-subtypes-and-clinicopathological-parameters" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/194529.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">8</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1564</span> Epidemiological, Clinical, Histopathological Profile and Management of Breast Cancer at Kinshasa University Clinics </h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Eddy%20K.%20Mukadi">Eddy K. Mukadi</a> </p> <p class="card-text"><strong>Abstract:</strong></p> This work is a documentary and descriptive study devoted to the epidemiological, clinical, histopathological and therapeutic profile of breast cancer deals with the department of gynecology and obstetrics of the university clinics of Kinshasa during the period from 1 January 2014 to 31 December 2014. We have identified 56 cases of breast cancer. These cancers accounted for 45.2% of gynecological mammary cancers. The youngest in our series was 18 years old while the oldest was 74 years old; And the mean age of these patients was 43.4 years and mostly multiparous (35.7%). Brides (60.7%) and bachelors (26.8%) were the most affected by breast cancer. The reasons for consultation were dominated by nodules in the breast (48.2%) followed by pain (35.7%) and nipple discharge (14.3%). In 89.2% of the cases, it was the advanced clinical stage (stage 3 and 4) and the infiltrating ductal carcinoma was the most frequent histological type (75%) The malignant tumor was mainly in the left breast (55.3%), and chemotherapy with hormone therapy and patey was the most convenient treatment (42.8%), while patey mastectomy was performed in 12.5% of patients. Because of the high incidence of breast cancer identified in our study, some preventive measures must be taken into account to address this public health problem, including breast autopalpation once a month, Early detection system development of a national breast cancer policy and the implementation of a national breast cancer control program. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=breast%20cancer" title="breast cancer">breast cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=histopathological%20profile" title=" histopathological profile"> histopathological profile</a>, <a href="https://publications.waset.org/abstracts/search?q=epidemiological%20profile" title=" epidemiological profile"> epidemiological profile</a>, <a href="https://publications.waset.org/abstracts/search?q=Kinshasa" title=" Kinshasa"> Kinshasa</a> </p> <a href="https://publications.waset.org/abstracts/74129/epidemiological-clinical-histopathological-profile-and-management-of-breast-cancer-at-kinshasa-university-clinics" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/74129.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">216</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1563</span> Molecular Study of P53- and Rb-Tumor Suppressor Genes in Human Papilloma Virus-Infected Breast Cancers</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Shakir%20H.%20Mohammed%20Al-Alwany">Shakir H. Mohammed Al-Alwany</a>, <a href="https://publications.waset.org/abstracts/search?q=Saad%20Hasan%20M.%20Ali"> Saad Hasan M. Ali</a>, <a href="https://publications.waset.org/abstracts/search?q=Ibrahim%20Mohammed%20S.%20Shnawa"> Ibrahim Mohammed S. Shnawa</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The study was aimed to define the percentage of detection of high-oncogenic risk types of HPV and their genotyping in archival tissue specimens that ranged from apparently healthy tissue to invasive breast cancer by using one of the recent versions of In Situ Hybridization(ISH) 0.2. To find out rational significance of such genotypes as well as over expressed products of mutants P53 and RB genes on the severity of underlying breast cancers. The DNA of HPV was detected in 46.5 % of tissues from breast cancers while HPV DNA in the tissues from benign breast tumours was detected in 12.5%. No HPV positive–ISH reaction was detected in healthy breast tissues of the control group. HPV DNA of genotypes (16, 18, 31 and 33) was detected in malignant group in frequency of 25.6%, 27.1%, 30.2% and 12.4%, respectively. Over expression of p53 was detected by IHC in 51.2% breast cancer cases and in 50% benign breast tumour group, while none of control group showed P53- over expression. Retinoblastoma protein was detected by IHC test in 49.7% of malignant breast tumours, 54.2% of benign breast tumours but no signal was reported in the tissues of control group. The significance prevalence of expression of mutated p53 & Rb genes as well as detection of high-oncogenic HPV genotypes in patients with breast cancer supports the hypothesis of an etiologic role for the virus in breast cancer development. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=human%20papilloma%20virus" title="human papilloma virus">human papilloma virus</a>, <a href="https://publications.waset.org/abstracts/search?q=P53" title=" P53"> P53</a>, <a href="https://publications.waset.org/abstracts/search?q=RB" title=" RB"> RB</a>, <a href="https://publications.waset.org/abstracts/search?q=breast%20cancer" title=" breast cancer"> breast cancer</a> </p> <a href="https://publications.waset.org/abstracts/5535/molecular-study-of-p53-and-rb-tumor-suppressor-genes-in-human-papilloma-virus-infected-breast-cancers" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/5535.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">480</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1562</span> Histological Grade Concordance between Core Needle Biopsy and Corresponding Surgical Specimen in Breast Carcinoma</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=J.%20Szpor">J. Szpor</a>, <a href="https://publications.waset.org/abstracts/search?q=K.%20Witczak"> K. Witczak</a>, <a href="https://publications.waset.org/abstracts/search?q=M.%20Storman"> M. Storman</a>, <a href="https://publications.waset.org/abstracts/search?q=A.%20Orchel"> A. Orchel</a>, <a href="https://publications.waset.org/abstracts/search?q=D.%20Hodorowicz-Zaniewska"> D. Hodorowicz-Zaniewska</a>, <a href="https://publications.waset.org/abstracts/search?q=K.%20Oko%C5%84"> K. Okoń</a>, <a href="https://publications.waset.org/abstracts/search?q=A.%20Klimkowska"> A. Klimkowska</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Core needle biopsy (CNB) is well established as an important diagnostic tool in diagnosing breast cancer and it is now considered the initial method of choice for diagnosing breast disease. In comparison to fine needle aspiration (FNA), CNB provides more architectural information allowing for the evaluation of prognostic and predictive factors for breast cancer, including histological grade—one of three prognostic factors used to calculate the Nottingham Prognostic Index. Several studies have previously described the concordance rate between CNB and surgical excision specimen in determination of histological grade (HG). The concordance rate previously ascribed to overall grade varies widely across literature, ranging from 59-91%. The aim of this study is to see how the data looks like in material at authors’ institution and are the results as compared to those described in previous literature. The study population included 157 women with a breast tumor who underwent a core needle biopsy for breast carcinoma and a subsequent surgical excision of the tumor. Both materials were evaluated for the determination of histological grade (scale from 1 to 3). HG was assessed only in core needle biopsies containing at least 10 well preserved HPF with invasive tumor. The degree of concordance between CNB and surgical excision specimen for the determination of tumor grade was assessed by Cohen’s kappa coefficient. The level of agreement between core needle biopsy and surgical resection specimen for overall histologic grading was 73% (113 of 155 cases). CNB correctly predicted the grade of the surgical excision specimen in 21 cases for grade 1 tumors (Kappa coefficient κ = 0.525 95% CI (0.3634; 0.6818), 52 cases for grade 2 (Kappa coefficient κ = 0.5652 95% CI (0.458; 0.667) and 40 cases for stage 3 tumors (Kappa coefficient κ = 0.6154 95% CI (0.4862; 0.7309). The highest level of agreement was observed in grade 3 malignancies. In 9 of 42 (21%) discordant cases, the grade was higher in the CNB than in the surgical excision. This composed 6% of the overall discordance. These results correspond to the noted in the literature, showing that underestimation occurs more frequently than overestimation. This study shows that authors’ institution’s histologic grading of CNBs and surgical excisions shows a fairly good correlation and is consistent with findings in previous reports. Despite the inevitable limitations of CNB, CNB is an effective method for diagnosing breast cancer and managing treatment options. Assessment of tumour grade by CNB is useful for the planning of treatment, so in authors’ opinion it is worthy to implement it in daily practice. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=breast%20cancer" title="breast cancer">breast cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=concordance" title=" concordance"> concordance</a>, <a href="https://publications.waset.org/abstracts/search?q=core%20needle%20biopsy" title=" core needle biopsy"> core needle biopsy</a>, <a href="https://publications.waset.org/abstracts/search?q=histological%20grade" title=" histological grade"> histological grade</a> </p> <a href="https://publications.waset.org/abstracts/136072/histological-grade-concordance-between-core-needle-biopsy-and-corresponding-surgical-specimen-in-breast-carcinoma" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/136072.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">230</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1561</span> Standard Protocol Selection for Acquisition of Breast Thermogram in Perspective of Early Breast Cancer Detection </h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Mrinal%20Kanti%20Bhowmik">Mrinal Kanti Bhowmik</a>, <a href="https://publications.waset.org/abstracts/search?q=Usha%20Rani%20Gogoi%20Jr."> Usha Rani Gogoi Jr.</a>, <a href="https://publications.waset.org/abstracts/search?q=Anjan%20Kumar%20Ghosh"> Anjan Kumar Ghosh</a>, <a href="https://publications.waset.org/abstracts/search?q=Debotosh%20Bhattacharjee"> Debotosh Bhattacharjee</a> </p> <p class="card-text"><strong>Abstract:</strong></p> In the last few decades, breast thermography has achieved an average sensitivity and specificity of 90% for breast tumor detection. Breast thermography is a non-invasive, cost-effective, painless and radiation-free breast imaging modality which makes a significant contribution to the evaluation and diagnosis of patients, suspected of having breast cancer. An abnormal breast thermogram may indicate significant biological risk for the existence or the development of breast tumors. Breast thermography can detect a breast tumor, when the tumor is in its early stage or when the tumor is in a dense breast. The infrared breast thermography is very sensitive to environmental changes for which acquisition of breast thermography should be performed under strictly controlled conditions by undergoing some standard protocols. Several factors like air, temperature, humidity, etc. are there to be considered for characterizing thermal images as an imperative tool for detecting breast cancer. A detailed study of various breast thermogram acquisition protocols adopted by different researchers in their research work is provided here in this paper. After going through a rigorous study of different breast thermogram acquisition protocols, a new standard breast thermography acquisition setup is proposed here in this paper for proper and accurate capturing of the breast thermograms. The proposed breast thermogram acquisition setup is being built in the Radiology Department, Agartala Government Medical College (AGMC), Govt. of Tripura, Tripura, India. The breast thermograms are captured using FLIR T650sc thermal camera with the thermal sensitivity of 20 mK at 30 degree C. The paper is an attempt to highlight the importance of different critical parameters of breast thermography like different thermography views, patient preparation protocols, acquisition room requirements, acquisition system requirements, etc. This paper makes an important contribution by providing a detailed survey and a new efficient approach on breast thermogram capturing. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=acquisition%20protocol" title="acquisition protocol">acquisition protocol</a>, <a href="https://publications.waset.org/abstracts/search?q=breast%20cancer" title=" breast cancer"> breast cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=breast%20thermography" title=" breast thermography"> breast thermography</a>, <a href="https://publications.waset.org/abstracts/search?q=infrared%20thermography" title=" infrared thermography "> infrared thermography </a> </p> <a href="https://publications.waset.org/abstracts/22190/standard-protocol-selection-for-acquisition-of-breast-thermogram-in-perspective-of-early-breast-cancer-detection" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/22190.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">397</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1560</span> Synchronous Carcinoma Cervix with Vulvar Carcinoma in situ: A Case Report</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Bhushan%20Bhalgat">Bhushan Bhalgat</a>, <a href="https://publications.waset.org/abstracts/search?q=Suresh%20Singh"> Suresh Singh</a>, <a href="https://publications.waset.org/abstracts/search?q=Phanindra%20Swain"> Phanindra Swain</a>, <a href="https://publications.waset.org/abstracts/search?q=Kamal%20Kishore%20Lakhera"> Kamal Kishore Lakhera</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Carcinoma of cervix and carcinoma of vulva have been associated with common predisposing factors like human papillomavirus and smoking. Skip metastases and metachronous appearance of both these tumours have been reported. There is no case report showing synchronous appearance of these tumours in English literature. We herewith report a case report of a middle aged female patient who presented with per vaginal bleeding, and on examination, a cervical mass was palpable. Also, a proliferative growth was seen over her left vulva. Biopsy of both lesions came out to be squamous cell carcinoma and carcinoma in situ, respectively. A radical hysterectomy and bilateral pelvic and paraaortic lymph nodal dissection was performed along with left simple vulvectomy. This thereby underscores that any lesion over vulva appearing during or after treatment of cervical carcinoma should be biopsied to rule out vulvar carcinoma. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=carcinoma%20of%20cervix" title="carcinoma of cervix">carcinoma of cervix</a>, <a href="https://publications.waset.org/abstracts/search?q=carcinoma%20of%20vulva" title=" carcinoma of vulva"> carcinoma of vulva</a>, <a href="https://publications.waset.org/abstracts/search?q=synchronous%20tumours" title=" synchronous tumours"> synchronous tumours</a>, <a href="https://publications.waset.org/abstracts/search?q=gynecological%20oncology" title=" gynecological oncology"> gynecological oncology</a> </p> <a href="https://publications.waset.org/abstracts/125647/synchronous-carcinoma-cervix-with-vulvar-carcinoma-in-situ-a-case-report" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/125647.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">171</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1559</span> Comparison of the Curvizigzag Incision with Transverse Stewart Incision in Women Undergoing Modified Radical Mastectomy for Carcinoma Breast</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=John%20Joseph%20S.%20Martis">John Joseph S. Martis</a>, <a href="https://publications.waset.org/abstracts/search?q=Rohanchandra%20R.%20Gatty"> Rohanchandra R. Gatty</a>, <a href="https://publications.waset.org/abstracts/search?q=Aaron%20Jose%20Fernandes"> Aaron Jose Fernandes</a>, <a href="https://publications.waset.org/abstracts/search?q=Rahul%20P.%20Nambiar"> Rahul P. Nambiar</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction: Surgery for breast cancer is either mastectomy or breast conservation surgery. The most commonly used incision for modified radical mastectomy is the transverse Stewart incision. But this incision may have the disadvantage of causing disparity between the closure lines of superior and inferior skin flaps in mastectomy and can cause overhanging of soft tissue below and behind the axilla. The curvizigzag incision, on principle, may help in this regard and can prevent scar migration beyond the anterior axillary line. This study aims to compare the two incisions in this regard. Methods: 100 patients with cancer of breast were included in the study after satisfying inclusion and exclusion criteria. They underwent surgery at Father Muller Medical College, Mangalore, India, between November 2019 to September 2021. The patients were divided into two groups. Group A patients were subjected to modified radical mastectomy with curvizigzag incision and group B patients with transverse Stewart incision. Results: Seroma on postoperative day1, day 2 was 0% in both the groups. Seroma on postoperative day 30 was present in 14% of patients in group B. 60% of patients in group B had sag of soft tissue below and behind the axilla, and none of the patients in group A had this problem. In 64% of the patients in group B, the incision crossed the anterior axillary fold, 64% of the patients in group B had tension in the incision site while approximation of the skin flaps. Conclusion: Curvizigzag incision is statistically better with lesser complications when compared to the transverse Stewart incision for modified radical mastectomy for carcinoma breast. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=breast%20cancer" title="breast cancer">breast cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=curvizigzag%20incision" title=" curvizigzag incision"> curvizigzag incision</a>, <a href="https://publications.waset.org/abstracts/search?q=transverse%20Stewart%20incision" title=" transverse Stewart incision"> transverse Stewart incision</a>, <a href="https://publications.waset.org/abstracts/search?q=seroma" title=" seroma"> seroma</a>, <a href="https://publications.waset.org/abstracts/search?q=modified%20radical%20mastectomy" title=" modified radical mastectomy"> modified radical mastectomy</a> </p> <a href="https://publications.waset.org/abstracts/153834/comparison-of-the-curvizigzag-incision-with-transverse-stewart-incision-in-women-undergoing-modified-radical-mastectomy-for-carcinoma-breast" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/153834.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">95</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1558</span> Effect of Copper Complexes on Human Colon Carcinoma Cell Line and Human Breast Carcinoma Cell Line</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Katar%C3%ADna%20Ko%C5%88arikov%C3%A1">Katarína Koňariková</a>, <a href="https://publications.waset.org/abstracts/search?q=Georgios%20A.%20Perdikaris"> Georgios A. Perdikaris</a>, <a href="https://publications.waset.org/abstracts/search?q=Lucia%20Andrez%C3%A1lov%C3%A1"> Lucia Andrezálová</a>, <a href="https://publications.waset.org/abstracts/search?q=Zde%C5%88ka%20%C4%8Eura%C4%8Dkov%C3%A1"> Zdeňka Ďuračková</a>, <a href="https://publications.waset.org/abstracts/search?q=Lucia%20Laubertov%C3%A1"> Lucia Laubertová</a>, <a href="https://publications.waset.org/abstracts/search?q=Helena%20Gbelcov%C3%A1"> Helena Gbelcová</a>, <a href="https://publications.waset.org/abstracts/search?q=Ingrid%20%C5%BDit%C5%88anov%C3%A1"> Ingrid Žitňanová </a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction: The continuous demand for new anti-cancer drugs has stimulated chemotherapeutic research based on the use of essential metalloelements with the aim to develop potential drugs with lower toxicity and higher antiproliferative activity against tumors. Copper(II) and its complexes play an important role as suitable species for antiproliferative tests. Objectives: The central objective of the current study was to investigate the potential in vitro anti-proliferative effects of N-salicylidene-L-glutamato copper (II) complexes and molecular mechanism of apoptosis induced by tested complexes. In our project we tested N-salicylidene-L-glutamato copper (II) complexes ZK1 - [Cu(N-salicylidene-L-glutamato)(H2O)2].H2O; MK0 - ([Cu2(N-sal-D,L-glu)2(isoquinoline)2].2H2O); MK1 - [Cu(N-salicylidene-5-methyl-L-glutamato)(H2O)].H2O; MK3 - transbis(ethanol)tetrakis(imidazol)Cu(II)(2+)bis(N-salicylidene-D,L-glutamato-N,O)-KO:KO´-(imidazol); MK5 - [Cu(N-salicylidene-D,L- glutamato)(2-methylimidazol] at concentration range 0.001-100 µmol/L against human colon carcinoma cell line HT-29 and human breast carcinoma cell line MCF-7. Methods: Viability was assessed by direct counting of 0.4% trypan blue dye-excluding cells after 24, 48 and 72 hour cultivations with or without copper complex and by MTT assay. To analyze the type of cell death and its mechanism induced by our copper complex we used different methods. To distinguish apoptosis from necrosis we used electrophoretic analysis, to study the activity of caspases 8 and 9 – luminometric analysis and caspase activity 3 colorimetric assay. Results: The observed anti-proliferative effect of the copper complexes appeared to be dose-, time- and cell line- dependent. Human colon carcinoma cells HT-29 appeared to be more sensitive to the complex MK0 ([Cu2(N-sal-D,L-glu)2(isoquinoline)2].2H2O) than to ZK1 ([Cu(N-salicylidene-L-glutamato)(H2O)2].H2O) and MK1 ([Cu(N-salicylidene-5-methyl-L-glutamato)(H2O)].H2O)). Human colon carcinoma cells HT-29 appeared to be more sensitive to the complex than human breast carcinoma cells MCF-7. IC50 decreased with time of incubation (24, 48 and 72h) for HT-29, but increased for MCF-7. By electrophoresis we found apoptotic cell death induced by our copper complexes in HT-29 at concentrations 1, 10, 50 and 100 µmol/L after 48h (ZK1) and 72h (MK0, MK1) and in MCF-7 we did not find apoptosis. We also studied molecular mechanism of apoptosis in HT-29 induced by copper complexes. We found active caspase 9 in HT-29 after ZK1 ([Cu(N-salicylidene-L-glutamato)(H2O)2].H2O) and MK1 ([Cu(N-salicylidene-5-methyl-L-glutamato)(H2O)].H2O)) influence and active caspase 8 after MK0 ([Cu2(N-sal-D,L-glu)2(isoquinoline)2].2H2O) influence. Conclusion: Our copper complexes showed cytotoxic activities against human colon carcinoma cells HT-29 and breast cancer cell line MCF-7 in vitro. Apoptosis was activated by mitochondrial pathway (intrinsic pathway) in case of ZK1 [Cu(N-salicylidene-L-glutamato)(H2O)2].H2O; MK1 [Cu(N-salicylidene-5-methyl-L-glutamato)(H2O)].H2O; MK3 - transbis(ethanol)tetrakis(imidazol)Cu(II)(2+)bis(N-salicylidene-D,L-glutamato-N,O)-KO:KO´-(imidazol) and MK5 - [Cu(N-salicylidene-D,L- glutamato)(2-methylimidazol] copper complexes and by death receptors (extrinsic pathway) in case of MK0 [Cu2(N-sal-D,L-glu)2(isoquinoline)2].2H2O copper complex in HT-29. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=apoptosis" title="apoptosis">apoptosis</a>, <a href="https://publications.waset.org/abstracts/search?q=copper%20complex" title=" copper complex"> copper complex</a>, <a href="https://publications.waset.org/abstracts/search?q=cancer" title=" cancer"> cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=carcinoma%20cell%20line" title=" carcinoma cell line"> carcinoma cell line</a> </p> <a href="https://publications.waset.org/abstracts/7794/effect-of-copper-complexes-on-human-colon-carcinoma-cell-line-and-human-breast-carcinoma-cell-line" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/7794.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">293</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1557</span> Tocilizumab Suppresses the Pro-carcinogenic Effects of Breast Cancer-associated Fibroblasts Through Inhibition of the STAT3/AUF1 Pathway</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Naif%20Al-Jomah">Naif Al-Jomah</a>, <a href="https://publications.waset.org/abstracts/search?q=Falah%20H%20Al-Mohanna"> Falah H Al-Mohanna</a>, <a href="https://publications.waset.org/abstracts/search?q=Abdelilah%20Aboussekhra"> Abdelilah Aboussekhra</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Active breast cancer-associated fibroblasts (CAFs), the most influential cells in breast tumor microenvironment, express/secrete high levels of the proinvasive/metastatic interleukin-6 (IL-6). Therefore, we have tested here the effect of the IL-6 receptor (IL-6R) inhibitor tocilizumab (TCZ; Actemra) on different active breast CAFs. We have shown that TCZ potently and persistently suppresses the expression of various CAF biomarkers, namely α-SMA, SDF-1 as well as the STAT3 pathway and its downstream target AUF1. TCZ also inhibited the proliferation, migration and invasion abilities of active breast CAF cells. Additionally, TCZ repressed the ability of CAF cells in promoting epithelial-to-mesenchymal transition, and enhancing the migratory/invasive and proliferative capacities of breast cancer cells in vitro. Importantly, these findings were confirmed in orthotopic humanized breast tumors in mice. Furthermore, TCZ suppressed the expression of the pro-angiogenic factor VEGF-A and its transactivator HIF-1α in CAF cells, and consequently inhibited the angiogenic-promoting effect of active CAFs both in vitro and in orthotopic tumor xenografts. These results indicate that inhibition of the IL-6/STAT3/AUF1 pathway by TCZ can normalize active breast CAFs and suppress their paracrine pro-carcinogenic effects, which paves the way toward development of specific CAF-targeting therapy, badly needed for more efficient breast cancer treatments. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=angiogenesis" title="angiogenesis">angiogenesis</a>, <a href="https://publications.waset.org/abstracts/search?q=interleukin-6" title=" interleukin-6"> interleukin-6</a>, <a href="https://publications.waset.org/abstracts/search?q=paracrine" title=" paracrine"> paracrine</a>, <a href="https://publications.waset.org/abstracts/search?q=cancer-associated%20fibroblasts" title=" cancer-associated fibroblasts"> cancer-associated fibroblasts</a> </p> <a href="https://publications.waset.org/abstracts/154395/tocilizumab-suppresses-the-pro-carcinogenic-effects-of-breast-cancer-associated-fibroblasts-through-inhibition-of-the-stat3auf1-pathway" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/154395.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">98</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1556</span> Thermalytix: An Advanced Artificial Intelligence Based Solution for Non-Contact Breast Screening</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=S.%20Sudhakar">S. Sudhakar</a>, <a href="https://publications.waset.org/abstracts/search?q=Geetha%20Manjunath"> Geetha Manjunath</a>, <a href="https://publications.waset.org/abstracts/search?q=Siva%20Teja%20Kakileti"> Siva Teja Kakileti</a>, <a href="https://publications.waset.org/abstracts/search?q=Himanshu%20Madhu"> Himanshu Madhu </a> </p> <p class="card-text"><strong>Abstract:</strong></p> Diagnosis of breast cancer at early stages has seen better clinical and survival outcomes. Survival rates in developing countries like India are very low due to accessibility and affordability issues of screening tests such as Mammography. In addition, Mammography is not much effective in younger women with dense breasts. This leaves a gap in current screening methods. Thermalytix is a new technique for detecting breast abnormality in a non-contact, non-invasive way. It is an AI-enabled computer-aided diagnosis solution that automates interpretation of high resolution thermal images and identifies potential malignant lesions. The solution is low cost, easy to use, portable and is effective in all age groups. This paper presents the results of a retrospective comparative analysis of Thermalytix over Mammography and Clinical Breast Examination for breast cancer screening. Thermalytix was found to have better sensitivity than both the tests, with good specificity as well. In addition, Thermalytix identified all malignant patients without palpable lumps. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=breast%20cancer%20screening" title="breast cancer screening">breast cancer screening</a>, <a href="https://publications.waset.org/abstracts/search?q=radiology" title=" radiology"> radiology</a>, <a href="https://publications.waset.org/abstracts/search?q=thermalytix" title=" thermalytix"> thermalytix</a>, <a href="https://publications.waset.org/abstracts/search?q=artificial%20intelligence" title=" artificial intelligence"> artificial intelligence</a>, <a href="https://publications.waset.org/abstracts/search?q=thermography" title=" thermography"> thermography</a> </p> <a href="https://publications.waset.org/abstracts/87848/thermalytix-an-advanced-artificial-intelligence-based-solution-for-non-contact-breast-screening" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/87848.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">291</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1555</span> Isolation of Cytotoxic Compound from Tectona grandis Stem to Be Used as Thai Medicinal Preparation for Cancer Treatment</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Onmanee%20Prajuabjinda">Onmanee Prajuabjinda</a>, <a href="https://publications.waset.org/abstracts/search?q=Pakakrong%20Thondeeying"> Pakakrong Thondeeying</a>, <a href="https://publications.waset.org/abstracts/search?q=Jipisute%20Chunthorng-Orn"> Jipisute Chunthorng-Orn</a>, <a href="https://publications.waset.org/abstracts/search?q=Bhanuz%20Dechayont"> Bhanuz Dechayont</a>, <a href="https://publications.waset.org/abstracts/search?q=Arunporn%20Itharat"> Arunporn Itharat </a> </p> <p class="card-text"><strong>Abstract:</strong></p> A Thai medicinal preparation has been used for cancer treatment more than ten years ago in Khampramong Temple. Tectona grandis stem is one ingredient of this Thai medicinal remedy. The ethanolic extract of Tectona grandis stem showed the highest cytotoxic activities against human breast adenocarcinoma (MCF-7), but was less cytotoxic against large cell lung carcinoma (COR-L23) (IC50 = 3.92 and 7.78 µg/ml, respectively). It was isolated by bioassay-guided isolation method. Tectoquinone, a anthraquinone compound was isolated from this plant. This compound showed high specific cytotoxicity against human breast adenocarcinoma (MCF-7), but was less cytotoxic against large cell lung carcinoma (COR-L23)(IC50 =16.15 and 47.56 µg/ml or 72.67 and 214.00 µM, respectively). However, it showed less cytotoxic activity than the crude extract. In conclusion, tectoquinone as a main compound, is not the best cytotoxic compound from Tectona grandis, so there are more active cytotoxic compounds in this extract which should be isolated in the future. Moreover, tectoquinone displayed specific cytotoxicity against only human breast adenocarcinoma (MCF-7) which is a good criterion for cancer treatment. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=Tectona%20grandis" title="Tectona grandis">Tectona grandis</a>, <a href="https://publications.waset.org/abstracts/search?q=SRB%20assay" title=" SRB assay"> SRB assay</a>, <a href="https://publications.waset.org/abstracts/search?q=cytotoxicity" title=" cytotoxicity"> cytotoxicity</a>, <a href="https://publications.waset.org/abstracts/search?q=tectoquinone" title=" tectoquinone"> tectoquinone</a> </p> <a href="https://publications.waset.org/abstracts/25415/isolation-of-cytotoxic-compound-from-tectona-grandis-stem-to-be-used-as-thai-medicinal-preparation-for-cancer-treatment" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/25415.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">432</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1554</span> Impact of Mammographic Screening on Ethnic Inequalities in Breast Cancer Stage at Diagnosis and Survival in New Zealand</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Sanjeewa%20Seneviratne">Sanjeewa Seneviratne</a>, <a href="https://publications.waset.org/abstracts/search?q=Ian%20Campbell"> Ian Campbell</a>, <a href="https://publications.waset.org/abstracts/search?q=Nina%20Scott"> Nina Scott</a>, <a href="https://publications.waset.org/abstracts/search?q=Ross%20Lawrenson"> Ross Lawrenson</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction: Indigenous Māori women experience a 60% higher breast cancer mortality rate compared with European women in New Zealand. We explored the impact of difference in the rate of screen detected breast cancer between Māori and European women on more advanced disease at diagnosis and lower survival in Māori women. Methods: All primary in-situ and invasive breast cancers diagnosed in screening age women (as defined by the New Zealand National Breast Cancer Screening Programme) between 1999 and 2012 in the Waikato area were identified from the Waikato Breast Cancer Register and the national screening database. Association between screen versus non-screen detection and cancer stage at diagnosis and survival were compared by ethnicity and socioeconomic deprivation. Results: Māori women had 50% higher odds of being diagnosed with more advance staged cancer compared with NZ European women, a half of which was explained by the lower rate of screen detected cancer in Māori women. Significantly lower breast cancer survival rates were observed for Māori compared with NZ European and most deprived compared with most affluent socioeconomic groups for symptomatically detected breast cancer. No significant survival differences by ethnicity or socioeconomic deprivation were observed for screen detected breast cancer. Conclusions: Low rate of screen detected breast cancer appears to be a major contributor for more advanced stage disease at diagnosis and lower breast cancer survival in Māori compared with NZ European women. Increasing screening participation for Māori has the potential to substantially reduce breast cancer mortality inequity between Māori and NZ European women. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=breast%20cancer" title="breast cancer">breast cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=screening" title=" screening"> screening</a>, <a href="https://publications.waset.org/abstracts/search?q=ethnicity" title=" ethnicity"> ethnicity</a>, <a href="https://publications.waset.org/abstracts/search?q=inequity" title=" inequity"> inequity</a> </p> <a href="https://publications.waset.org/abstracts/11325/impact-of-mammographic-screening-on-ethnic-inequalities-in-breast-cancer-stage-at-diagnosis-and-survival-in-new-zealand" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/11325.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">514</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1553</span> Factors Contributing to Delayed Diagnosis and Treatment of Breast Cancer and Its Outcome in Jamhoriat Hospital Kabul, Afghanistan</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Ahmad%20Jawad%20Fardin">Ahmad Jawad Fardin</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Over 60% of patients with breast cancer in Afghanistan present late with advanced stage III and IV, a major cause for the poor survival rate. The objectives of this study were to identify the contributing factors for the diagnosis and treatment delay and its outcome. This cross-sectional study was conducted on 318 patients with histologically confirmed breast cancer in the oncology department of Jamhoriat hospital, which is the first and only national cancer center in Afghanistan; data were collected from medical records and interviews conducted with women diagnosed with breast cancer, linear regression and logistic regression were used for analysis. Patient delay was defined as the time from first recognition of symptoms until first medical consultation and doctor form first consultation with a health care provider until histological confirmation of breast cancer. The mean age of patients was 49.2+_ 11.5years. The average time for the final diagnosis of breast cancer was 8.5 months; most patients had ductal carcinoma 260.7 (82%). Factors associated with delay were low education level 76% poor socioeconomic and cultural conditions 81% lack of cancer center 73% lack of screening 19%. The stage distribution was as follows stage IV 4 22% stage III 44.4% stage II 29.3% stage I 4.3%. Complex associated factors were identified to delayed the diagnosis of breast cancer and increased adverse outcomes consequently. Raising awareness and education in women, the establishment of cancer centers and providing accessible diagnosis service and screening, training of general practitioners; required to promote early detection, diagnosis and treatment. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=delayed%20diagnosis%20and%20poor%20outcome" title="delayed diagnosis and poor outcome">delayed diagnosis and poor outcome</a>, <a href="https://publications.waset.org/abstracts/search?q=breast%20cancer%20in%20Afghanistan" title=" breast cancer in Afghanistan"> breast cancer in Afghanistan</a>, <a href="https://publications.waset.org/abstracts/search?q=poor%20outcome%20of%20delayed%20breast%20cancer%20treatment" title=" poor outcome of delayed breast cancer treatment"> poor outcome of delayed breast cancer treatment</a>, <a href="https://publications.waset.org/abstracts/search?q=breast%20cancer%20delayed%20diagnosis%20and%20treatment%20in%20Afghanistan" title=" breast cancer delayed diagnosis and treatment in Afghanistan"> breast cancer delayed diagnosis and treatment in Afghanistan</a> </p> <a href="https://publications.waset.org/abstracts/141760/factors-contributing-to-delayed-diagnosis-and-treatment-of-breast-cancer-and-its-outcome-in-jamhoriat-hospital-kabul-afghanistan" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/141760.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">183</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1552</span> Value of FOXP3 Expression in Prediction of Neoadjuvant Chemotherapy Effect in Triple Negative Breast Cancer</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Badawia%20Ibrahim">Badawia Ibrahim</a>, <a href="https://publications.waset.org/abstracts/search?q=Iman%20Hussein"> Iman Hussein</a>, <a href="https://publications.waset.org/abstracts/search?q=Samar%20El%20Sheikh"> Samar El Sheikh</a>, <a href="https://publications.waset.org/abstracts/search?q=Fatma%20Abou%20Elkasem"> Fatma Abou Elkasem</a>, <a href="https://publications.waset.org/abstracts/search?q=Hazem%20Abo%20Ismael"> Hazem Abo Ismael</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: Response of breast carcinoma to neoadjuvant chemotherapy (NAC) varies regarding many factors including hormonal receptor status. Breast cancer is a heterogenous disease with different outcomes, hence a need arises for new markers predicting the outcome of NAC especially for the triple negative group when estrogen, progesterone receptors and Her2/neu are negative. FOXP3 is a promising target with unclear role. Aim: To examine the value of FOXP3 expression in locally advanced triple negative breast cancer tumoral cells as well as tumor infiltrating lymphocytes (TILs) and to elucidate its relation to the extent of NAC response. Material and Methods: Forty five cases of immunohistochemically confirmed to be triple negative breast carcinoma were evaluated for NAC (Doxorubicin, Cyclophosphamide AC x 4 cycles + Paclitaxel x 12 weeks, patients with ejection fraction less than 60% received Taxotere or Cyclophosphamide, Methotrexate, Fluorouracil CMF) response in both tumour and lymph nodes status according to Miller & Payne's and Sataloff's systems. FOXP3 expression in tumor as well as TILs evaluated in the pretherapy biopsies was correlated with NAC response in breast tumor and lymph nodes as well as other clinicopathological factors. Results: Breast tumour cells showed FOXP3 positive cytoplasmic expression in (42%) of cases. High FOXP3 expression percentage was detected in (47%) of cases. High infiltration by FOXP3+TILs was detected in (49%) of cases. Positive FOXP3 expression was associated with negative lymph node metastasis. High FOXP3 expression percentage and high infiltration by FOXP3+TILs were significantly associated with complete therapy response in axillary lymph nodes. High FOXP3 expression in tumour cells was associated with high infiltration by FOXP3+TILs. Conclusion: This result may provide evidence that FOXP3 marker is a good prognostic and predictive marker for triple negative breast cancer (TNBC) indicated for neoadjuvant chemotherapy and can be used for stratifications of TNBC cases indicated for NAC. As well, this study confirmed the fact that the tumour cells and the surrounding microenvironment interact with each other and the tumour microenvironment can influence the treatment outcomes of TNBC. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=breast%20cancer" title="breast cancer">breast cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=FOXP3%20expression" title=" FOXP3 expression"> FOXP3 expression</a>, <a href="https://publications.waset.org/abstracts/search?q=prediction%20of%20neoadjuvant%20chemotherapy%20effect" title=" prediction of neoadjuvant chemotherapy effect"> prediction of neoadjuvant chemotherapy effect</a>, <a href="https://publications.waset.org/abstracts/search?q=triple%20negative" title=" triple negative "> triple negative </a> </p> <a href="https://publications.waset.org/abstracts/60312/value-of-foxp3-expression-in-prediction-of-neoadjuvant-chemotherapy-effect-in-triple-negative-breast-cancer" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/60312.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">275</span> </span> </div> </div> <ul class="pagination"> <li class="page-item disabled"><span class="page-link">&lsaquo;</span></li> <li class="page-item active"><span class="page-link">1</span></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=invasive%20breast%20carcinoma%20%28IBC%29&page=2">2</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=invasive%20breast%20carcinoma%20%28IBC%29&page=3">3</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=invasive%20breast%20carcinoma%20%28IBC%29&page=4">4</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=invasive%20breast%20carcinoma%20%28IBC%29&page=5">5</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=invasive%20breast%20carcinoma%20%28IBC%29&page=6">6</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=invasive%20breast%20carcinoma%20%28IBC%29&page=7">7</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=invasive%20breast%20carcinoma%20%28IBC%29&page=8">8</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=invasive%20breast%20carcinoma%20%28IBC%29&page=9">9</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=invasive%20breast%20carcinoma%20%28IBC%29&page=10">10</a></li> <li class="page-item disabled"><span class="page-link">...</span></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=invasive%20breast%20carcinoma%20%28IBC%29&page=52">52</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=invasive%20breast%20carcinoma%20%28IBC%29&page=53">53</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=invasive%20breast%20carcinoma%20%28IBC%29&page=2" rel="next">&rsaquo;</a></li> </ul> </div> </main> <footer> <div id="infolinks" class="pt-3 pb-2"> <div class="container"> <div style="background-color:#f5f5f5;" class="p-3"> <div class="row"> <div class="col-md-2"> <ul class="list-unstyled"> About <li><a href="https://waset.org/page/support">About Us</a></li> <li><a href="https://waset.org/page/support#legal-information">Legal</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/WASET-16th-foundational-anniversary.pdf">WASET celebrates its 16th foundational anniversary</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Account <li><a href="https://waset.org/profile">My Account</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Explore <li><a href="https://waset.org/disciplines">Disciplines</a></li> <li><a href="https://waset.org/conferences">Conferences</a></li> <li><a href="https://waset.org/conference-programs">Conference Program</a></li> <li><a href="https://waset.org/committees">Committees</a></li> <li><a href="https://publications.waset.org">Publications</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Research <li><a href="https://publications.waset.org/abstracts">Abstracts</a></li> <li><a href="https://publications.waset.org">Periodicals</a></li> <li><a href="https://publications.waset.org/archive">Archive</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Open Science <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Science-Philosophy.pdf">Open Science Philosophy</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Science-Award.pdf">Open Science Award</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Society-Open-Science-and-Open-Innovation.pdf">Open Innovation</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Postdoctoral-Fellowship-Award.pdf">Postdoctoral Fellowship Award</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Scholarly-Research-Review.pdf">Scholarly Research Review</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Support <li><a href="https://waset.org/page/support">Support</a></li> <li><a href="https://waset.org/profile/messages/create">Contact Us</a></li> <li><a href="https://waset.org/profile/messages/create">Report Abuse</a></li> </ul> </div> </div> </div> </div> </div> <div class="container text-center"> <hr style="margin-top:0;margin-bottom:.3rem;"> <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank" class="text-muted small">Creative Commons Attribution 4.0 International License</a> <div id="copy" class="mt-2">© 2024 World Academy of Science, Engineering and Technology</div> </div> </footer> <a href="javascript:" id="return-to-top"><i class="fas fa-arrow-up"></i></a> <div class="modal" id="modal-template"> <div class="modal-dialog"> <div class="modal-content"> <div class="row m-0 mt-1"> <div class="col-md-12"> <button type="button" class="close" data-dismiss="modal" aria-label="Close"><span aria-hidden="true">×</span></button> </div> </div> <div class="modal-body"></div> </div> </div> </div> <script src="https://cdn.waset.org/static/plugins/jquery-3.3.1.min.js"></script> <script src="https://cdn.waset.org/static/plugins/bootstrap-4.2.1/js/bootstrap.bundle.min.js"></script> <script src="https://cdn.waset.org/static/js/site.js?v=150220211556"></script> <script> jQuery(document).ready(function() { /*jQuery.get("https://publications.waset.org/xhr/user-menu", function (response) { jQuery('#mainNavMenu').append(response); });*/ jQuery.get({ url: "https://publications.waset.org/xhr/user-menu", cache: false }).then(function(response){ jQuery('#mainNavMenu').append(response); }); }); </script> </body> </html>